Bladder Cancer Playbook for Urologists: Practical Application of Current and Emerging Strategies to Optimize Patient Outcomes

Release Date: June 17, 2020
Expiration Date: June 17, 2021

Activity Overview

The bladder cancer treatment landscape is broadening with advances in immuno-oncology and targeted therapy strategies, while new clinical data continue to impact all stages of bladder cancer as more is learned about single-agent and combination immunotherapy approaches. In addition, novel agents tailored to treat bladder cancer with specific genomic alterations are being explored, as well as therapeutic options for disease that is refractory to immune checkpoint inhibitor therapy.

This enduring CME activity from a live webcast on June 4, 2020, features a panel of experts who will address the application of immune-based and targeted-agent approaches through presentations and discussions of the most recent clinical data for the treatment of early and advanced bladder cancer. Practical patient case scenarios will highlight treatment decisions in various bladder cancer settings and will address the management of adverse events associated with immunotherapy and targeted agents, the importance of multidisciplinary care, and future directions in the field of bladder cancer.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Target Audience

This educational program is directed toward urologists, oncologists, and researchers interested in the treatment of bladder cancers. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with bladder cancers are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Identify the biologic rationale for using immune-based and targeted therapy approaches to treat bladder cancer
• Evaluate data from pivotal clinical trials of immunotherapies, signaling inhibitors, and other emerging agents for bladder cancer
• Discuss novel agents and combinatorial approaches under investigation for the treatment of bladder cancer across multiple settings, including advanced/metastatic, muscle-invasive, and non–muscle-invasive disease
• Consider practice-changing evidence from clinical trials of immunotherapies, cytotoxic agents, and targeted therapies during multidisciplinary, team-based care planning for patients with bladder cancer
• Outline frequent and less common toxicities associated with newer agents used in the treatment of bladder cancer, including immunotherapies and targeted agents, and best practices for their mitigation and management

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Arjun V. Balar, MD
Associate Professor, Department of Medicine
NYU Grossman School of Medicine
Director, Genitourinary Medical Oncology Program
NYU Langone Perlmutter Cancer Center
New York, NY

Disclosures: Grant Research Support: AstraZeneca plc/MedImmune LLC, Genentech Inc, Immunomedics Inc, Merck & Co Inc, Nektar Therapeutics, Seattle Genetics Inc; Consultant: AstraZeneca plc/MedImmune LLC, Genentech Inc, Incyte Corporation, Janssen Pharmaceuticals Inc, Merck & Co Inc, Pfizer Inc, Nektar Therapeutics, Seattle Genetics Inc; Other: Steering/scientific advisory committee for Merck & Co Inc; Steering committee membership for Nektar Therapeutics; Speaking engagements for AstraZeneca plc/MedImmune LLC, Genentech Inc, and Merck & Co Inc.

Robert Dreicer, MD, MS, MACP, FASCO, Faculty Chair
Professor of Medicine and Urology
University of Virginia School of Medicine
Section Head, Medical Oncology
Associate Director for Clinical Research
Deputy Director, University of Virginia Cancer Center
Codirector, Paul Mellon Urologic Cancer Institute
Charlottesville, VA

Disclosures: Grant Research Support: Exelixis Inc, Janssen Pharmaceuticals Inc, Seattle Genetics Inc; Consultant: Astellas Pharma US Inc, Eisai Co Ltd, Genentech Inc, Merck & Co Inc, Novartis AG, Orion Corporation, Pfizer Inc, Seattle Genetics Inc.

Leonard G. Gomella, MD, FACS
The Bernard W. Godwin, Jr, Professor of Prostate Cancer
Chairman, Department of Urology
Sidney Kimmel Medical College
Senior Director, Clinical Affairs, Sidney Kimmel Cancer Center
Urology Service Line Director Jefferson Health
Thomas Jefferson University
Philadelphia, PA

Disclosures: Grant Research Support: NCI through NRG as Urology Chair; Consultant: AstraZeneca plc, Ferring Pharmaceuticals, Merck & Co Inc, TAP Pharmaceuticals.

Neal Shore, MD, FACS
Director, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, SC

Disclosures: Consultant: AbbVie Inc, Amgen Inc, Astellas Pharma US Inc, A2 Biotherapeutics Inc, Bayer AG, Bristol Myers Squibb Company, Clovis Oncology Inc, Dendreon Pharmaceuticals LLC, FerGene Inc, Ferring Pharmaceuticals, Myovant Sciences Ltd, Tolmar Pharmaceuticals Inc, Nymox Pharmaceutical Corporation, MDX Pharma, Janssen Pharmaceuticals Inc, Merck & Co Inc, Pfizer Inc, Sanofi Genzyme; Speaker Bureau: Astellas Pharma US Inc, Bayer AG, Janssen Pharmaceuticals Inc.

The staff Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.